Cubist Systematic Strategies’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $318K | Buy |
+63,821
| New | +$295K | ﹤0.01% | 2471 |
|
|
2025
Q1 | – | Sell |
-108,835
| Closed | -$521K | – | 3583 |
|
|
2024
Q4 | $521K | Buy |
108,835
+9,493
| +10% | +$45.6K | ﹤0.01% | 2159 |
|
|
2024
Q3 | $466K | Buy |
+99,342
| New | +$533K | ﹤0.01% | 2240 |
|
|
2024
Q2 | – | Sell |
-18,529
| Closed | -$76.2K | – | 4090 |
|
|
2024
Q1 | $76.2K | Sell |
18,529
-124,288
| -87% | -$498K | ﹤0.01% | 3314 |
|
|
2023
Q4 | $603K | Sell |
142,817
-76,493
| -35% | -$309K | ﹤0.01% | 2425 |
|
|
2023
Q3 | $947K | Buy |
219,310
+93,794
| +75% | +$521K | 0.01% | 1917 |
|
|
2023
Q2 | $827K | Buy |
125,516
+98,557
| +366% | +$632K | 0.01% | 2071 |
|
|
2023
Q1 | $183K | Sell |
26,959
-306,676
| -92% | -$2.16M | ﹤0.01% | 3267 |
|
|
2022
Q4 | $2.47M | Buy |
333,635
+160,162
| +92% | +$1.56M | 0.01% | 1677 |
|
|
2022
Q3 | $1.71M | Buy |
173,473
+96,519
| +125% | +$1.02M | 0.01% | 2160 |
|
|
2022
Q2 | $839K | Sell |
76,954
-5,961
| -7% | -$61.8K | 0.01% | 2614 |
|
|
2022
Q1 | $938K | Sell |
82,915
-14,972
| -15% | -$197K | 0.01% | 2080 |
|
|
2021
Q4 | $1.54M | Buy |
97,887
+59,166
| +153% | +$1.03M | 0.01% | 1600 |
|
|
2021
Q3 | $664K | Sell |
38,721
-6,981
| -15% | -$122K | 0.01% | 1838 |
|
|
2021
Q2 | $983K | Sell |
45,702
-68,742
| -60% | -$1.23M | 0.01% | 1587 |
|
|
2021
Q1 | $1.72M | Buy |
114,444
+79,078
| +224% | +$1.28M | 0.02% | 1144 |
|
|
2020
Q4 | $465K | Sell |
35,366
-48,512
| -58% | -$584K | 0.01% | 1811 |
|
|
2020
Q3 | $810K | Sell |
83,878
-19,715
| -19% | -$211K | 0.01% | 1459 |
|
|
2020
Q2 | $1.19M | Buy |
103,593
+82,112
| +382% | +$930K | 0.02% | 1082 |
|
|
2020
Q1 | $223K | Sell |
21,481
-65,071
| -75% | -$807K | 0.01% | 1679 |
|
|
2019
Q4 | $1.42M | Sell |
86,552
-17,027
| -16% | -$257K | 0.03% | 945 |
|
|
2019
Q3 | $1.38M | Buy |
103,579
+20,815
| +25% | +$290K | 0.03% | 816 |
|
|
2019
Q2 | $1.17M | Buy |
82,764
+17,565
| +27% | +$280K | 0.02% | 954 |
|
|
2019
Q1 | $1.2M | Buy |
65,199
+40,746
| +167% | +$928K | 0.04% | 666 |
|
|
2018
Q4 | $639K | Sell |
24,453
-44,758
| -65% | -$1.05M | 0.03% | 804 |
|
|
2018
Q3 | $1.59M | Buy |
+69,211
| New | +$1.41M | 0.09% | 294 |
|
|
2018
Q1 | – | Sell |
-2,357
| Closed | -$36K | – | 2091 |
|
|
2017
Q4 | $36K | Sell |
2,357
-23,030
| -91% | -$342K | ﹤0.01% | 1802 |
|
|
2017
Q3 | $454K | Buy |
25,387
+17,485
| +221% | +$293K | 0.03% | 888 |
|
|
2017
Q2 | $129K | Sell |
7,902
-6,097
| -44% | -$87.9K | 0.01% | 1406 |
|
|
2017
Q1 | $196K | Buy |
13,999
+1,235
| +10% | +$17.6K | 0.01% | 1195 |
|
|
2016
Q4 | $204K | Sell |
12,764
-1,941
| -13% | -$31.2K | 0.02% | 1249 |
|
|
2016
Q3 | $245K | Buy |
+14,705
| New | +$198K | 0.02% | 1138 |
|
|
2015
Q4 | – | Sell |
-16,976
| Closed | -$191K | – | 1962 |
|
|
2015
Q3 | $191K | Buy |
+16,976
| New | +$208K | 0.01% | 1488 |
|
Other funds holding VNDA
TCM
KAM
Cubist Systematic Strategies's VNDA Position: Q3 2025 in Review
Cubist Systematic Strategies opened a new position in Vanda Pharmaceuticals (VNDA) in Q3 2025: 63,821 shares worth $318K. The stake represents ﹤0.01% of the portfolio and ranks #2471 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in VNDA as recently as Q4 2024.
Cubist Systematic Strategies first reported a position in VNDA in Q3 2015 and has held it in 33 quarters since. The position peaked at $2.47M in Q4 2022. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.
- Cubist Systematic Strategies held 63,821 shares of Vanda Pharmaceuticals worth $318K as of Q3 2025.
- Vanda Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
- Vanda Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2471 holding.
- Cubist Systematic Strategies first reported a position in Vanda Pharmaceuticals in Q3 2015 and has held it in 33 quarters since.
- Cubist Systematic Strategies's Vanda Pharmaceuticals position peaked at $2.47M in Q4 2022.
- 150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.